文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

放疗在寡转移性前列腺癌根治性治疗中的应用:约翰霍普金斯经验

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-08-13

该研究回顾性分析了156例接受根治性放疗的寡转移性前列腺癌患者,中位随访24.6个月。全队列中位生化无进展生存期(bPFS)为12.9个月,1年bPFS率为52%;围放疗期雄激素剥夺治疗(ADT)、较低肿瘤体积和激素敏感状态与更长的bPFS相关。转移导向治疗总体毒性低,但疗效因OPCa亚型而异。

要点

  • 全队列中位bPFS为12.9个月,1年bPFS率为52%。
  • 激素敏感患者中位bPFS为17.2个月,去势抵抗患者为7.2个月(P < .0001)。
  • 围放疗期ADT、较低肿瘤体积和激素敏感状态与延长bPFS相关。

核心结论

  • 转移导向治疗对多种寡转移性前列腺癌亚型有效,但疗效存在差异。

研究设计与样本

  • 回顾性纳入156例接受根治性放疗的寡转移性前列腺癌患者,共354个转移灶,中位随访24.6个月。

主要发现

  • 全队列中位bPFS为12.9个月,1年bPFS率为52%。
  • 24个月局部失败累积发生率为7.4%。
  • 激素敏感患者中位bPFS为17.2个月,去势抵抗患者为7.2个月(P < .0001)。
  • 24个月局部失败累积发生率在激素敏感患者中为4.8%,去势抵抗患者中为12.1%(P = .034)。
  • 150例有毒性数据的患者中,53例(35%)发生急性1级毒性,8例(5%)发生2级毒性,无3级毒性;仅13例(9%)出现晚期毒性。

关键数值与推荐

  • 多因素分析显示,围放疗期ADT、较低大体肿瘤体积和激素敏感状态与延长bPFS相关。
  • 中位至下一次干预时间(包括重复放疗)为21.6个月。
  • 28例激素敏感患者接受围放疗期ADT(中位4.3个月)且睾酮恢复,中位随访33.5个月时20例未出现bPFS,中位bPFS未达到,24个月bPFS率为77%。

临床怎么用

  • 对于寡转移性前列腺癌,可考虑转移导向放疗,尤其激素敏感且肿瘤体积较小的患者。
  • 围放疗期ADT可能改善bPFS,但需结合激素状态个体化决策。

局限性

  • 回顾性单中心研究,样本量有限,随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The use of radiation therapy (RT) in consolidating oligometastatic prostate cancer (OPCa) is a rapidly evolving treatment paradigm. We review our institutional experience using metastasis-directed therapy in the definitive management of men with OPCa. METHODS AND MATERIALS: Patients with OPCa treated with definitive RT were included. The Kaplan-Meier method and multivariable Cox regression analysis were performed to assess biochemical progression-free survival (bPFS) and time to next intervention. Cumulative incidence functions were used to calculate rates of local failure. Toxicity was assessed using Common Terminology Criteria for Adverse Events (version 4). RESULTS: This study analyzed 156 patients with OPCa and 354 metastatic lesions with median follow-up of 24.6 months. Of 150 patients with toxicity data, 53 (35%) experienced acute grade 1 toxicity, 8 (5%) had grade 2, and none had grade 3 toxicity. Only 13 patients (9%) had late toxicities. At 24 months, the cumulative incidence of local failure was 7.4%. Median bPFS for the entire cohort was 12.9 months and 52% at 1 year. On multivariable analysis, factors associated with prolonged bPFS were peri-RT androgen deprivation therapy (ADT), lower gross tumor volume, and hormone-sensitive (HS) OPCa. Median time to next intervention, including repeat RT, was 21.6 months. Median bPFS for men with HS prostate cancer was 17.2 months compared with 7.2 months in men with castrate-resistant OPCa (P < .0001), and cumulative incidence of local failure at 24 months was lower with HS OPCa (4.8% vs 12.1%; P = .034). We analyzed 28 men with HS OPCa treated with a course of peri-RT ADT (median, 4.3 months) with recovery of testosterone. At a median follow-up of 33.5 months, 20 patients had not developed bPFS, median bPFS had not been reached, and 24-month bPFS was 77%. CONCLUSIONS: Metastasis-directed therapy can be effective across a wide range of OPCa subtypes, but with differential efficacy. Further study is warranted to investigate the use of RT across the wide range of patients with OPCa.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Deek MP, Yu C, Phillips R, et al. Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. Int J Radiat Oncol Biol Phys. 2019. PMID: 31419509. doi:10.1016/j.ijrobp.2019.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。